Skip to main content

Table 3 Drug related adverse events in the safety population (n = 31), including any AE experienced by ≥5% of the cohort and all grade 3 AEs. Note that there were no grade 4 or 5 drug related AEs

From: A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

Toxicity category Description Grade 1–2 Percent Grade 3 Percent
Blood and lymphatic system disorders Anemia 5 16.1% - -
Cardiac disorders Atrial fibrillation - - 1 3.2%
Endocrine disorders Hypophysitis 1 3.2% 1 3.2%
Hypothyroidism 2 6.5% 1 3.2%
Eye disorders Dry Eye 3 9.7% - -
Gastrointestinal disorders Abdominal Pain 2 6.5% - -
Colitis 2 6.5% 2 6.5%
Constipation 4 12.9% - -
Diarrhea 17 54.8% - -
Dry Mouth 5 16.1% - -
Flatulence 2 6.5% - -
Nausea 16 51.6% 2 6.5%
Vomiting 8 25.8% 1 3.2%
General disorders and administration site conditions Chills 19 61.3% - -
Fatigue 28 90.3% 1 3.2%
Fever 15 48.4% - -
Flu like symptoms 7 22.6% - -
Injection site reaction 7 22.6% - -
Infusion reaction 3 9.7% - -
Malaise 3 9.7% - -
Night Sweats 4 12.9% - -
Investigations Alanine aminotransferase increased 8 25.8% - -
Alkaline phosphatase increased 2 6.5% - -
Aspartate aminotransferase increased 8 25.8% - -
Lymphocyte count decreased 4 12.9% 1 3.2%
Neutrophil count decreased 3 9.7% 3 9.7%
Platelet count decreased 6 19.4% - -
Weight loss 5 16.1% - -
White blood cell decreased 8 25.8% 2 6.5%
Metabolism and nutrition disorders Anorexia 16 51.6% - -
Dehydration 1 3.2% 2 6.5%
Hyponatremia - - 2 6.5%
Muskuloskeletal and connective tissue disorders Arthralgia 15 48.4% 1 3.2%
Myalgia 2 6.5% - -
Nervous system disorders Dizziness 5 16.1% - -
Dysgeusia 8 25.8% - -
Headache 17 54.8% - -
Syncope - - 1 3.2%
Psychiatric disorders Anxiety 3 9.7% - -
Depression 5 16.1% - -
Respiratory, thoracic and mediastinal disorders Cough 7 22.6% - -
Dyspnea 8 25.8% - -
Productive Cough 2 6.5% - -
Skin and subcutaneous tissue disorders Alopecia 6 19.4% - -
Dry Skin 4 12.9% - -
Pruritus 18 58.1% 2 6.5%
Rash 22 71.0% 4 12.9%
Skin hypopigmentation 7 22.6% - -
Any   31 100% 15 48.4%